SCHEMBL5850108

SCHEMBL5850108

CC(C)c1c[nH]c(CC(=O)c2ccccc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
GLA P06280 1/20 0.42
RAB9A P51151 7/20 0.41
NPC1 O15118 4/20 0.41
ALDH1A1 P00352 7/20 0.39
MAPT P10636 6/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
LMNA P02545 4/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
APAF1 O14727 1/20 0.39
MITF O75030 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 4/20 0.38
MAPK1 P28482 2/20 0.38
CYP3A4 P08684 2/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4969955 0.80 RAB9A (0.47) KDM4EGLARAB9ANPC1ALDH1A1
SCHEMBL5849864 0.77 RAB9A (0.47) KDM4EGLARAB9ANPC1ALDH1A1
SCHEMBL11268098 0.77 RAB9A (0.47) KDM4EGLARAB9ANPC1ALDH1A1
SCHEMBL7664922 0.73 TAAR1 (0.43) RAB9ANPC1LMNAKMT2APOLB
SCHEMBL24787891 0.69 RIPK1 (0.40) TRPA1
SCHEMBL4903117 0.69 TSHR (0.46) ALDH1A1LMNAHTTKMT2AHPGD
SCHEMBL5523498 0.68 NPC1 (0.47) KDM4EGLARAB9ANPC1ALDH1A1
SCHEMBL4968860 0.67 GAA (0.61) KDM4EGLARAB9ANPC1ALDH1A1
Hydrochloric Acid SCHEMBL5850214 0.67 RAB9A (0.46) KDM4EGLARAB9ANPC1ALDH1A1
Isobutane SCHEMBL1801676 0.67 MAPT (0.63) KDM4ERAB9ANPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6984646-B2 Imidazopyridinones as p38 map kinase inhibitors BAYER HEALHCARE AG (DE) 2006-01-10 US disclosed
EP-1412353-B1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS BAYER HEALTHCARE AG (DE) 2005-03-02 EP disclosed
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors BAYER HEALTHCARE AG (DE) 2004-11-04 US disclosed
EP-1412353-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS Bayer HealthCare AG (DE) 2004-04-28 EP disclosed
WO-2003008413-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS BAYER HEALTHCARE AG (DE) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors MAPK1, MAPK3, MAP3K1 KDM4E 1759/4885GLA 3954/4885RAB9A 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.